Tagged: chemistry
11 results
Integrated Biosciences
Integrated Biosciences is a Redwood City biotech founded in 2022 that fuses optogenetics, chemistry, and AI to discover small-molecule drugs for age-related diseases. Its optogenetic screening platform uses light to control cellular biology at millisecond and micron scale, generating clean data to train an explainable-AI drug-discovery engine. The company has published in Nature - including a new structural class of antibiotics - and raised $17.2M in seed funding led by Sutter Hill Ventures.
Ben Hernandez
Ben Hernandez is the founder and CEO of Numat, a Chicago deep-tech company that treats chemistry like software. Numat designs metal-organic frameworks (MOFs), nanoscale materials that capture, hold, and even destroy specific molecules with atomic precision. Trained as an engineer with a law degree and an MBA, and a former private equity investor, Hernandez turned a Northwestern lab idea into the world's first industrial-scale MOF manufacturing campus, powering safer hazardous-gas storage for the semiconductor industry through its ION-X product and pushing toward industrial decarbonization.
Atinary Technologies
Atinary Technologies is a Swiss-American deeptech startup whose no-code SDLabs platform pairs machine learning with lab robotics to run Self-Driving Labs - closed-loop experiments that learn and adapt on the fly, accelerating R&D in chemistry, materials, pharma and climate tech by orders of magnitude.
Adam Slavney
Adam Slavney is the co-founder and CEO of Pascal, a Cambridge, Massachusetts startup commercializing solid-state refrigerants to replace the planet-warming gases inside air conditioners, heat pumps, refrigerators and data centers. A Stanford-trained chemist who studied perovskite solar cells before a Harvard postdoc in clean-energy economics, Slavney spun Pascal out of Harvard in 2023 around a class of barocaloric materials that respond to pressure two orders of magnitude more strongly than other solids. The company raised an $8M seed round in 2024 led by Engine Ventures, with Khosla Ventures participating, and later added a Series A to scale prototypes. Slavney's pitch is blunt: heating and cooling burn nearly 40% of the world's energy and the refrigerants doing it cause about 2% of global warming, and he wants to keep the cooling while deleting the climate cost.
Andrew Chadeayne
Andrew Chadeayne is the founder and CEO of CaaMTech, an Issaquah, Washington psychedelic pharmaceutical company building safer, patentable psychedelic-inspired medicines. A chemist (PhD, Cornell) and patent attorney (JD, George Washington) who began his career proving sugar is addictive through opioid pathways, he has filed more than 100 patent applications mapping the chemistry of psilocybin, tryptamines and other psychedelics. His strategy is to expand 'the universe of available compounds' rather than bet on a single molecule, giving researchers a toolbox of characterized psychedelics for mental health treatment.
Numat
Numat is a Chicago-based advanced-materials company and the first to commercialize metal-organic frameworks (MOFs) at industrial scale. Its molecularly engineered, programmable 'sponges' capture, store, and separate hazardous chemicals for semiconductor, defense, and energy customers, reducing the impact of chemical products and processes on human health and the environment.
Albert Invent
Albert Invent builds an AI-native operating system for chemists and materials scientists, unifying electronic lab notebooks, LIMS, regulatory compliance and predictive AI into one cloud platform that aims to compress decades-long R&D cycles into weeks.
Nick Talken
Nick Talken is the Co-Founder and CEO of Albert Invent, an Oakland-based AI platform that is transforming how chemists and materials scientists do research and development. A chemical engineer by training who learned to code, Talken spent years inside Henkel's global R&D organization before spinning out Albert Invent in 2022 with a team of co-founders who built the product from within. The company's platform - used by over 3,000 scientists across 142+ labs in 30+ countries at companies like Kenvue, Henkel, and Chemours - has raised over $52 million from top-tier investors including Coatue, Index Ventures, TCV, and J.P. Morgan Private Capital.
Chris Emerson
Chris Emerson, PhD, is the Founder, Chief Scientist, and CEO of LEVEL, California's #1 cannabis tablet brand. A US Navy veteran and Chinese interpreter turned small-molecule chemist, he abandoned a Stanford postdoc in 2012 to spend four months living in a tent on a Mendocino cannabis farm - and emerged with a founding thesis that would reshape how the industry thinks about getting high. Instead of chasing THC percentages, he built LEVEL around effects-driven cannabinoid formulations using precise ratios of acidic, neutral, and degradative compounds the plant alone can't deliver. Two US patents, multiple peer-reviewed publications, and an IRB-approved clinical trial later, LEVEL is the top-selling cannabis tablet brand in California, now operating in seven states.
Stig Hansen
Stig K. Hansen is a Danish-American biochemist and serial biotech founder who co-founded Kimia Therapeutics in 2023, a Berkeley-based precision chemistry company applying machine learning and automated synthesis to drug discovery. He previously co-founded and led Carmot Therapeutics for 15 years, inventing Chemotype Evolution technology that contributed to LUMAKRAS - the world's first FDA-approved KRAS G12C inhibitor for non-small cell lung cancer. Carmot was acquired by Roche for up to $3.1 billion in January 2024. At Kimia, Hansen is pioneering the ATLAS platform (AcTive Learning with Automated Synthesis and Screening), which integrates high-throughput chemistry, genome editing, and AI to map druggable chemical space at unprecedented scale. The company raised a $55 million Series A in December 2023 led by The Column Group and Dimension.
Yoneda Labs
Yoneda Labs is building the foundation model for chemical manufacturing - think of it as the AI brain that tells chemists exactly which conditions to use to make a reaction work, before they spend months running dead-end experiments. Founded by three Cambridge graduates and backed by Khosla Ventures and Y Combinator, the company's software suite (Predict, Optimize, Analyze) compresses reaction optimization timelines from months to days. Their first named partnership with Symeres pushed cross-coupling reaction yields from ~30% to over 90%. The goal: become the universal AI layer for the $5 trillion chemical industry.